Table 1:
Clinical and demographic characteristics of patients with compensated liver cirrhosis and hepatitis C virus infection.
| Parameter | Percentage (%) or average (range) |
|---|---|
| Male gender | 49.2% |
| IFN Pre-treated patients (relapsers/non-responders) | 67.3% (39.1%/57.3%) |
| Co-morbidities | 37.3% |
| HBs-Ag positive patients | 34/2068 (1.6%) |
| Class A Child Pugh score (6 points) | 216/2068 (10.44%) |
| Class B Child Pugh score (7 points) | 11/2068 (0.5%) |
| BMI | 27.2 (16.84÷44.9) |
| Age | 60 (25÷82) years |
| ALT | 88 (19 ÷ 604) IU/ml |
| AST | 77 (20 ÷ 431) IU/ml |
| Platelets | 133000/ mm3 (12000 ÷ 650000) |
| Total bilirubin | 0,9 (0,1 ÷ 3.61) mg/dl |
| INR | 1.11 (0.34 ÷3) |
| MELD | 8.09 (6 ÷ 22) |
| e Cl Cr | 98 (15 ÷ 347) ml/min |
| Blood glucose | 105 (60 ÷ 454) mg/dl |
| Severe non-alcoholic steatohepatitis* | 50.1% |
| Severe necroinflammation (grade 3 or 4 by Fibromax)* | 67.5% |
* estimated through FibroMax™ (Biopredictive, Paris, France)
IFN= Interferon; e Cl Cr= estimated clearance creatinine